#JustReleased AAO Preferred Practice Pattern 2018 for Dry Ey
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The American Academy of Ophthalmology (AAO) has updated its 2013 Preferred Practice Pattern guidelines on dry eye syndrome also known as dry eye disease.

Dry eye, either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads patients to seek ophthalmologic care. Even though these symptoms often improve with treatment, the disease usually is not curable, which may be a source of patient and physician frustration. Importantly, dry eye is also a cause of reduced visual function and may compromise results of corneal, cataract, and refractive surgery.

“Patient education is an important aspect of successful management of this condition. The ophthalmologist should educate the patient about the natural history and chronic nature of dry eye. Realistic expectations for therapeutic goals should be set and discussed with the patient. Patient education is an important aspect of successful management of this condition.” The authors write in the guidance document.

Highlighted findings and recommendations for care include the following:-
• No single test is adequate for establishing the diagnosis of dry eye. The constellation of findings from multiple tests can add greatly to the clinician’s understanding of the patient’s condition.

• Pharmacological and procedural treatments are associated with improvements in patient symptoms and clinical signs, although chronic therapy and patient compliance are necessary in most instances.

• Omega-3 fatty acid products without ethyl esters have been recommended and widely used in the treatment of dry eye. However, a prospective, multicenter, masked large-scale trial of 3000 mg of omega-3 fatty acids for 12 months did not show any benefit in patient symptoms or signs over placebo.

• Topical cyclosporine treatment has long been used in the treatment of dry eye and shown to have clinical benefits. Topical cyclosporine, in some instances, leads to long-term treatment-free remission of patient symptoms and signs.

• Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to treat dry eye syndrome (also known as dry eye disease), but the exact mechanism of action of lifitegrast in dry eye is unknown.
- Topical lifitegrast 5% has been approved by the US Food and Drug Administration for treatment of dry eye. Published studies show benefit in signs (corneal and conjunctival staining) as well as symptoms (eye dryness score and ocular discomfort) over a period of 3 months.
- Although the drug seems to be safe over 12 months, long-term efficacy and side effects are unknown.

• Dry eye patients considering keratorefractive surgery, particularly LASIK, should be cautioned that the dry eye condition could become worse after surgery. Dry eye symptoms are common in the first few months after surgery and tend to subside with time. Patients can safely undergo LASIK surgery if a pre-existing dry eye condition can be improved preoperatively.

• Dry eye is one of the main reasons for patient dissatisfaction following cataract surgery. Dry eye symptoms that continue beyond the normal postoperative period of 3 months might be seen in about one third of individuals. Baseline ocular surface and tear film parameters predict the patients at risk. Therefore, all patients undergoing cataract surgery should be evaluated and managed for dry eye preoperatively.

• Approximately 1/10 patients with clinically significant dry eye have an underlying Sjӧgren syndrome
- A recent meta-analysis found that, among autoimmune diseases, primary Sjӧgren syndrome is the most strongly associated risk factor for malignancy, with an incidence rate of 18.9%.
- Therefore timely diagnosis and appropriate management of patients with underlying Sjӧgren syndrome is relevant.

About AAO
The American Academy of Ophthalmology (Academy) is a professional medical association of ophthalmologists. It is headquartered in San Francisco, California. The Academy's stated mission is "to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology."

Note: This list is a brief compilation of some of the key recommendations included in the Guidelines and is not exhaustive and does not constitute medical advice. Kindly refer to the original publication here: https://pxmd.co/5raBj
Dr. A●●●●i M●●●a and 2 other likes this
Dr. D●●p J●●●i
Dr. D●●p J●●●i Ophthalmology
Very useful information
Nov 15, 2018Like